CAS
ANAB icon

Coppell Advisory Solutions’s AnaptysBio ANAB Stock Holding History

Coppell Advisory Solutions’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
+3,638
New +$221K 1.37% 15
2024
Q3 		– Sell
-714
Closed -$17.9K – 1878
2024
Q2 		$17.9K Buy
+714
New +$16.6K ﹤0.01% 834

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Coppell Advisory Solutions's ANAB Position: Q2 2026 in Review

Coppell Advisory Solutions opened a new position in AnaptysBio (ANAB) in Q2 2026: 3,638 shares worth $16.6M. The stake represents 1.37% of the portfolio and ranks #15 among its holdings. This is a return to the name: Coppell Advisory Solutions previously reported a position in ANAB as recently as Q2 2024.

Coppell Advisory Solutions first reported a position in ANAB in Q2 2024 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Coppell Advisory Solutions held 3,638 shares of AnaptysBio worth $16.6M as of Q2 2026.
  • AnaptysBio was a new Coppell Advisory Solutions position in Q2 2026.
  • AnaptysBio made up 1.37% of Coppell Advisory Solutions's portfolio in Q2 2026, its #15 holding.
  • Coppell Advisory Solutions first reported a position in AnaptysBio in Q2 2024 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Coppell Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.